Our current study suggests unrecognized functionality of FFD as a protective agent against IBD through a novel mechanism of targeting cPLA2, which may provide innovative interventions to develop cPLA2 targeting treatment in IBD and other inflammatory autoimmune diseases as well. The gene discussed is PLA2G4A; the disease is inflammatory bowel disease.